The natural history of multiple system atrophy: a prospective European cohort study

@article{Wenning2013TheNH,
  title={The natural history of multiple system atrophy: a prospective European cohort study},
  author={Gregor K. Wenning and Felix Geser and Florian Krismer and Klaus Seppi and Susanne Duerr and Sylvia Boesch and Martin K{\"o}llensperger and Georg Goebel and Karl Peter Pfeiffer and Paolo Barone and Maria Teresa Pellecchia and Niall P. Quinn and Vasiliki Koukouni and Clare J. Fowler and Anette E Schrag and Christopher J. Mathias and Nir Giladi and Tanya Gurevich and E. Dupont and Karen Ostergaard and Christer Nilsson and H{\aa}kan Widner and Wolfgang Hermann Oertel and Karla Eggert and Alberto Albanese and Francesca del Sorbo and Eduardo Tolosa and Adriana Cardozo and G{\"u}nther Deuschl and Helge Hellriegel and Thomas Klockgether and Richard C. Dodel and Cristina Sampaio and Miguel Coelho and Ruth Djaldetti and Eldad Melamed and Thomas Gasser and Christoph Kamm and Giuseppe Meco and Carlo Colosimo and Olivier Rascol and Wassilios G. Meissner and Francois Tison and Werner Poewe},
  journal={The Lancet. Neurology},
  year={2013},
  volume={12},
  pages={264 - 274}
}
Summary Background Multiple system atrophy (MSA) is a fatal and still poorly understood degenerative movement disorder that is characterised by autonomic failure, cerebellar ataxia, and parkinsonism in various combinations. Here we present the final analysis of a prospective multicentre study by the European MSA Study Group to investigate the natural history of MSA. Methods Patients with a clinical diagnosis of MSA were recruited and followed up clinically for 2 years. Vital status was… Expand
Natural History of Multiple System Atrophy in North America: A Prospective Cohort Study
TLDR
The first North American prospective natural history study of MSA, and the effects of phenotype and autonomic failure on prognosis, is reported, finding severe symptomatic autonomic Failure at diagnosis is associated with worse prognosis. Expand
Multiple system atrophy in Hokkaido, Japan: a prospective registry study of natural history and symptom assessment scales followed for 5 years
TLDR
MSA-C was dominant, but the use of antiparkinsonian drugs increased over the study period, and this study is the first large-scale prospective MSA cohort study in Asia. Expand
A milestone on the way to therapy for MSA
TLDR
It is found that the parkinsonian variant of MSA and incomplete bladder emptying were signifi cant predictors of survival and a shorter disease duration at baseline and an absent levodopa response predicted rapid progression on the UMSARS, which was designed and validated by the European MSA study group as a quantitative outcome measure. Expand
Clinical Features in a Danish Population-Based Cohort of Probable Multiple System Atrophy Patients
TLDR
A nationwide approach corroborated that MSA is associated with diverse and grave symptoms, only limited response to levodopa, and poor prognosis. Expand
Disease progression and prognostic factors in multiple system atrophy: A prospective cohort study
TLDR
From this large MSA cohort, it is confirmed the rapid progression and poor prognosis of MSA and provided additional evidence for a negative impact of early autonomic dysfunction and the severity of orthostatic hypotension on both disease progression and survival. Expand
Progression of Motor and Non-Motor Symptoms in Multiple System Atrophy: A Prospective Study from the Catalan-MSA Registry.
TLDR
Within 24 months and as early as 12 months, MSA cases may experience significant motor worsening, affecting basic daily activities, and not all clinical scales register a clear progression of symptoms. Expand
[Clinical picture and diagnostic criteria of multiple system atrophy].
TLDR
Novel diagnostic biomarkers, which have a potential for evaluation of the component of glial cytoplasmic inclusion such as alpha-synuclein radiotracer and serum and CSF alpha- synuclein levels may be a key way to support the diagnosis of patients at the stage of "mono system atrophy". Expand
Multiple system atrophy: Clinical, evolutive and histopathological characteristics of a series of cases.
TLDR
A better description of MSA features with standardized test confirmed by means of neuropathological studies could help to increase sensitivity. Expand
Pan-American Consortium of Multiple System Atrophy (PANMSA). A Pan-American multicentre cohort study of multiple system atrophy.
TLDR
The epidemiological and clinical data appears to be similar to other Western international series, however, of note, the MSA-C phenotype was predominant in Non-Caucasians, more specifically the Mestizo population, and this observation opens a new path to explore. Expand
Symptomatic medication of 97 patients with multiple system atrophy parkinsonian subtype: An observational study
TLDR
In the study the considerable proportion of MSA-P patients received high levels of dopaminergic medication chronically, and its efficacy on MSA is still uncertain and further studies with standardised clinical efficacy monitoring are highly welcome. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 61 REFERENCES
Potential outcome measures and trial design issues for multiple system atrophy
  • S. May, S. Gilman, +15 authors C. Shults
  • Medicine
  • Movement disorders : official journal of the Movement Disorder Society
  • 2007
TLDR
The UMSARS Motor Examination score exhibited the most favorable characteristics as an outcome measure for a therapeutic trial in MSA with 1 year of follow‐up, and seemed to capture disease progression. Expand
Progression of multiple system atrophy (MSA): A prospective natural history study by the European MSA Study Group (EMSA SG)
TLDR
This report is the first prospective study showing rapid annual UMSARS rates of decline in MSA, and the increases in Hoehn and Yahr (HY) Parkinson's disease staging, SE ADL and SS3 correlated significantly with U MSARS I, UMSAR II, and UMSars IV progression. Expand
Prospective differentiation of multiple system atrophy from Parkinson disease, with and without autonomic failure.
TLDR
Preliminary results of a prospective ongoing study of multiple system atrophy (MSA) and Parkinson disease (PD) suggest that autonomic function tests can separate MSA from PD, and that the primary lesion in PD is ganglionic and postganglionic, while MSA is pre Ganglionic. Expand
Progression of parkinsonism in multiple system atrophy
TLDR
This is the first observational study on UPDRS rates of decline in MSA and shows that motor progression appeared to be accelerated during the early disease stages, which is helpful for the planning of future therapeutic trials. Expand
Autopsy confirmed multiple system atrophy cases: Mayo experience and role of autonomic function tests
TLDR
The pattern of severe and progressive generalised autonomic failure with severe adrenergic and sudomotor failure combined with the clinical phenotype is highly predictive of MSA. Expand
Multiple system atrophy: natural history, MRI morphology, and dopamine receptor imaging with 123IBZM-SPECT.
TLDR
MRI and IBZM-SPECT provide in vivo evidence for combined basal ganglia and pontocerebellar involvement in almost all patients in this series. Expand
Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients.
TLDR
The interval from initial symptom to combined motor and autonomic dysfunction can predict functional deterioration and survival in MSA, and the relationship between atrophy and functional status was highly variable among the individuals, suggesting that other factors influenced the functional deterioration. Expand
The natural history of degenerative ataxia: a retrospective study in 466 patients.
TLDR
In FRDA, the time until confinement to wheelchair was shorter in patients with earlier disease onset, suggesting that patients with long GAA repeats and early disease onset have a poor prognosis, and in MSA, later age of onset increased the risk of rapid progression and death. Expand
Clinical features and natural history of multiple system atrophy. An analysis of 100 cases.
The clinical features and natural history of 100 patients diagnosed as probable multiple system atrophy (MSA) are described. In all 14 (of 41 deceased) cases who underwent post-mortem examination ofExpand
Disease Severity and Progression in Progressive Supranuclear Palsy and Multiple System Atrophy: Validation of the NNIPPS – PARKINSON PLUS SCALE
TLDR
Although MSA and PSP differed quantitatively on the total score at entry and on rate of progression, the relative contribution of clinical dimensions to overall severity and progression was similar and therefore is appropriate for use in clinical studies with PSP or MSA. Expand
...
1
2
3
4
5
...